Cancer metastases: challenges and opportunities

Seyfried, 2013, On the origin of cancer metastasis, Crit Rev Oncog, 18, 43, 10.1615/CritRevOncog.v18.i1-2.40

Damsky, 2014, Melanoma metastasis: new concepts and evolving paradigms, Oncogene, 33, 2413, 10.1038/onc.2013.194

Wells, 2013, Targeting tumor cell motility as a strategy against invasion and metastasis, Trends Pharmacol Sci, 34, 283, 10.1016/j.tips.2013.03.001

Weber, 2013, Why does cancer therapy lack effective anti-metastasis drugs?, Cancer Lett, 328, 207, 10.1016/j.canlet.2012.09.025

Hu, 2012, Notch signaling pathway and cancer metastasis, Adv Exp Med Biol, 727, 186, 10.1007/978-1-4614-0899-4_14

Daenen, 2011, Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells, Cancer Res, 71, 6976, 10.1158/0008-5472.CAN-11-0627

Eccles, 2007, Metastasis: recent discoveries and novel treatment strategies, Lancet, 369, 1742, 10.1016/S0140-6736(07)60781-8

Haraguchi, 2009, The role of the transcriptional regulator snail in cell detachment, reattachment and migration, Cell Adhes Migr, 3, 259, 10.4161/cam.3.3.8259

Zanotti, 2011, Fibroblasts from the muscles of Duchenne muscular dystrophy patients are resistant to cell detachment apoptosis, Exp Cell Res, 317, 2536, 10.1016/j.yexcr.2011.08.004

Sakamoto, 2010, Targeting anoikis resistance in prostate cancer metastasis, Mol Asp Med, 31, 205, 10.1016/j.mam.2010.02.001

Alizadeh, 2014, Metastasis review: from bench to bedside, Tumour Biol, 35, 8483, 10.1007/s13277-014-2421-z

Profumo, 2013, MicroRNAs: cobblestones on the road to cancer metastasis, Crit Rev Oncog, 18, 341, 10.1615/CritRevOncog.2013007182

Li, 2011, Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets, Breast Cancer Res Treat, 128, 7, 10.1007/s10549-011-1499-x

Bravo-Cordero, 2014, Spatial regulation of tumor cell protrusions by RhoC, Cell Adhes Migr, 8, 263, 10.4161/cam.28405

White, 2007, Multifaceted roles of integrins in breast cancer metastasis, J Mammary Gland Biol Neoplasia, 12, 135, 10.1007/s10911-007-9045-5

Jin, 2004, Integrins: roles in cancer development and as treatment targets, Br J Cancer, 90, 561, 10.1038/sj.bjc.6601576

Janik, 2010, Cell migration-the role of integrin glycosylation, Biochim Biophys Acta, 1800, 545, 10.1016/j.bbagen.2010.03.013

Pawelek, 2008, Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis, Nat Rev Cancer, 8, 377, 10.1038/nrc2371

Schlaepfer, 1998, Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events, Mol Cell Biol, 18, 2571, 10.1128/MCB.18.5.2571

Brooks, 1996, Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3, Cell, 85, 683, 10.1016/S0092-8674(00)81235-0

Deryugina, 1997, Matrix metalloproteinase-2 activation modulates glioma cell migration, J Cell Sci, 110, 2473, 10.1242/jcs.110.19.2473

Rivard, 2009, Phosphatidylinositol 3-kinase: a key regulator in adherens junction formation and function, Front Biosci (Landmark Ed), 14, 510, 10.2741/3259

Hazan, 2004, Cadherin switch in tumor progression, Ann NY Acad Sci, 1014, 155, 10.1196/annals.1294.016

Jiang, 1996, E-cadherin and its associated protein catenins, cancer invasion and metastasis, Br J Surg, 83, 437, 10.1002/bjs.1800830404

Pećina-Šlaus, 2003, Tumor suppressor gene E-cadherin and its role in normal and malignant cells, Cancer Cell Int, 3, 17, 10.1186/1475-2867-3-17

Riethmacher, 1995, A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development, Proc Natl Acad Sci U S A, 92, 855, 10.1073/pnas.92.3.855

Luo, 1999, Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection, Cancer Res, 59, 3552

Hsu, 2000, E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors, Am J Pathol, 156, 1515, 10.1016/S0002-9440(10)65023-7

Bogenrieder, 2003, Axis of evil: molecular mechanisms of cancer metastasis, Oncogene, 22, 6524, 10.1038/sj.onc.1206757

Larue, 1996, A role for cadherins in tissue formation, Development, 122, 3185, 10.1242/dev.122.10.3185

Hazan, 2000, Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis, J Cell Biol, 148, 779, 10.1083/jcb.148.4.779

Nieman, 1999, N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression, J Cell Biol, 147, 631, 10.1083/jcb.147.3.631

Bendas, 2012, Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins, Int J Cell Biol, 2012, 676731, 10.1155/2012/676731

Barclay, 2003, Membrane proteins with immunoglobulin-like domains—a master superfamily of interaction molecules, Semin Immunol, 15, 215, 10.1016/S1044-5323(03)00047-2

Wai Wong, 2012, The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis, Int J Cell Biol, 2012, 340296, 10.1155/2012/340296

Johnson, 1997, Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand, Int J Cancer, 73, 769, 10.1002/(SICI)1097-0215(19971127)73:5<769::AID-IJC26>3.0.CO;2-#

Wu, 2011, Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice, J Urol, 185, 1504, 10.1016/j.juro.2010.11.052

Zeng, 2011, Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells, BMC Cancer, 11, 113, 10.1186/1471-2407-11-113

Roland, 2007, ICAM-1 expression determines malignant potential of cancer, Surgery, 141, 705, 10.1016/j.surg.2007.01.016

Siesser, 2009, L1 cell adhesion molecules as regulators of tumor cell invasiveness, Cell Adhes Migr, 3, 275, 10.4161/cam.3.3.8689

Jezierska, 2006, ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy, Med Sci Monit, 12, BR263

Gavert, 2008, L1-CAM in cancerous tissues, Expert Opin Biol Ther, 8, 1749, 10.1517/14712598.8.11.1749

Friedl, 2009, Collective cell migration in morphogenesis, regeneration and cancer, Nat Rev Mol Cell Biol, 10, 445, 10.1038/nrm2720

Underhill, 1992, CD44: the hyaluronan receptor, J Cell Sci, 103, 293, 10.1242/jcs.103.2.293

Shimizu, 1989, Dual role of the CD44 molecule in T cell adhesion and activation, J Immunol, 143, 2457, 10.4049/jimmunol.143.8.2457

Trochon, 1996, Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro, Int J Cancer, 66, 664, 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4

Webb, 1990, LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release, Science, 249, 1295, 10.1126/science.1697984

Fox, 1994, Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms, Cancer Res, 54, 4539

Richter, 2012, The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation, Histochem Cell Biol, 137, 687, 10.1007/s00418-012-0916-5

Ponta, 2003, CD44: from adhesion molecules to signalling regulators, Nat Rev Mol Cell Biol, 4, 33, 10.1038/nrm1004

Ishii, 1993, CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen, Surg Oncol, 2, 255, 10.1016/0960-7404(93)90015-Q

Jalkanen, 1992, Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin, J Cell Biol, 116, 817, 10.1083/jcb.116.3.817

Naor, 1997, CD44: structure, function, and association with the malignant process, Adv Cancer Res, 71, 241, 10.1016/S0065-230X(08)60101-3

Marhaba, 2004, CD44 in cancer progression: adhesion, migration and growth regulation, J Mol Histol, 35, 211, 10.1023/B:HIJO.0000032354.94213.69

Legg, 2002, A novel PKC-regulated mechanism controls CD44-ezrin association and directional cell motility, Nat Cell Biol, 4, 399, 10.1038/ncb797

Lokeshwar, 1991, Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis, J Biol Chem, 266, 17983, 10.1016/S0021-9258(18)55226-1

Iczkowski, 2010, Cell adhesion molecule CD44: its functional roles in prostate cancer, Am J Transl Res, 3, 1

Aruffo, 1990, CD44 is the principal cell surface receptor for hyaluronate, Cell, 61, 1303, 10.1016/0092-8674(90)90694-A

Orian-Rousseau, 2010, CD44, a therapeutic target for metastasising tumours, Eur J Cancer, 46, 1271, 10.1016/j.ejca.2010.02.024

Buchheit, 2014, Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression, Nat Rev Cancer, 14, 632, 10.1038/nrc3789

Kirfel, 2004, Cell migration: mechanisms of rear detachment and the formation of migration tracks, Eur J Cell Biol, 83, 717, 10.1078/0171-9335-00421

Spano, 2012, Molecular networks that regulate cancer metastasis, Semin Cancer Biol, 22, 234, 10.1016/j.semcancer.2012.03.006

Jacob, 2015, The regulation of MMP targeting to invadopodia during cancer metastasis, Front Cell Dev Biol, 3, 4, 10.3389/fcell.2015.00004

Paz, 2014, Invading one step at a time: the role of invadopodia in tumor metastasis, Oncogene, 33, 4193, 10.1038/onc.2013.393

Wolf, 2009, Mapping proteolytic cancer cell-extracellular matrix interfaces, Clin Exp Metastasis, 26, 289, 10.1007/s10585-008-9190-2

Friedl, 2008, Tube travel: the role of proteases in individual and collective cancer cell invasion, Cancer Res, 68, 7247, 10.1158/0008-5472.CAN-08-0784

Yilmaz, 2010, Mechanisms of motility in metastasizing cells, Mol Cancer Res, 8, 629, 10.1158/1541-7786.MCR-10-0139

McAllister, 2014, The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis, Nat Cell Biol, 16, 717, 10.1038/ncb3015

Goubran, 2014, Regulation of tumor growth and metastasis: the role of tumor microenvironment, Cancer Growth Metastasis, 7, 9, 10.4137/CGM.S11285

Naora, 2014, Heterotypic cellular interactions in the ovarian tumor microenvironment: biological significance and therapeutic implications, Front Oncol, 4, 18, 10.3389/fonc.2014.00018

Wood, 2014, The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets, Cancer Treat Rev, 40, 558, 10.1016/j.ctrv.2013.10.001

Bournazou, 2013, Targeting the tumor microenvironment: JAK-STAT3 signaling, JAKSTAT, 2, e23828

Fang, 2013, Targeting the tumor microenvironment: from understanding pathways to effective clinical trials, Cancer Res, 73, 4965, 10.1158/0008-5472.CAN-13-0661

Chou, 2013, microRNA-mediated regulation of the tumor microenvironment, Cell Cycle, 12, 3262, 10.4161/cc.26087

Zhang, 2014, Microenvironmental regulation of cancer metastasis by miRNAs, Trends Cell Biol, 24, 153, 10.1016/j.tcb.2013.09.007

Jiang, 2011, Cancer metastasis, challenges, progress and the opportunities, Front Biosci (Elite Ed), 3, 391, 10.2741/e254

Xue, 2006, Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis, Cancer Res, 66, 192, 10.1158/0008-5472.CAN-05-1242

Ma, 2003, c-Met: structure, functions and potential for therapeutic inhibition, Cancer Metastasis Rev, 22, 309, 10.1023/A:1023768811842

Aguiar, 2014, New strategy to control cell migration and metastasis regulated by CCN2/CTGF, Cancer Cell Int, 14, 61, 10.1186/1475-2867-14-61

Micke, 2004, Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?, Lung Cancer, 45 Suppl 2, S163, 10.1016/j.lungcan.2004.07.977

Qian, 2003, Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production, Cancer Lett, 190, 105, 10.1016/S0304-3835(02)00517-7

Luker, 2006, Functions of CXCL12 and CXCR4 in breast cancer, Cancer Lett, 238, 30, 10.1016/j.canlet.2005.06.021

Burger, 2006, CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment, Blood, 107, 1761, 10.1182/blood-2005-08-3182

Shuman Moss, 2012, Matrix metalloproteinases: changing roles in tumor progression and metastasis, Am J Pathol, 181, 1895, 10.1016/j.ajpath.2012.08.044

Rawlings, 1994, Families of serine peptidases, Methods Enzymol, 244, 19, 10.1016/0076-6879(94)44004-2

Netzel-Arnett, 2003, Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer, Cancer Metastasis Rev, 22, 237, 10.1023/A:1023003616848

Duffy, 1988, Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report, Cancer, 62, 531, 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B

Keledjian, 2005, Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion, J Cell Biochem, 94, 374, 10.1002/jcb.20240

Keledjian, 2003, Anoikis induction by quinazoline based α1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of Bcl-2, J Urol, 169, 1150, 10.1097/01.ju.0000042453.12079.77

Rennebeck, 2005, Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?, Cancer Res, 65, 11230, 10.1158/0008-5472.CAN-05-2763

Schaefer, 2005, Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells, Cancer Res, 65, 2251, 10.1158/0008-5472.CAN-04-3037

Zhang, 2008, Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma, Oncology, 75, 17, 10.1159/000151615

Tanaka, 2009, Neurotrophic receptor, tropomyosin-related kinase B as an independent prognostic marker in gastric cancer patients, J Surg Oncol, 99, 307, 10.1002/jso.21232

Desmet, 2006, The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?, Cell Mol Life Sci, 63, 755, 10.1007/s00018-005-5490-8

Camoratto, 1997, CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity, Int J Cancer, 72, 673, 10.1002/(SICI)1097-0215(19970807)72:4<673::AID-IJC20>3.0.CO;2-B

Undevia, 2004, Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors, Investig New Drugs, 22, 449, 10.1023/B:DRUG.0000036687.26604.8c

Araujo, 2010, Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors, Cancer Treat Rev, 36, 492, 10.1016/j.ctrv.2010.02.015

Park, 2008, Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model, Cancer Res, 68, 3323, 10.1158/0008-5472.CAN-07-2997

Blaschuk, 1990, Identification of a cadherin cell adhesion recognition sequence, Dev Biol, 139, 227, 10.1016/0012-1606(90)90290-Y

Blaschuk, 2012, Discovery and development of N-cadherin antagonists, Cell Tissue Res, 348, 309, 10.1007/s00441-011-1320-5

Russo, 2013, A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells, Int J Oncol, 42, 83, 10.3892/ijo.2012.1708

Ganguly, 2013, Integrins and metastasis, Cell Adhes Migr, 7, 251, 10.4161/cam.23840

Alva, 2012, Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium, Investig New Drugs, 30, 749, 10.1007/s10637-010-9573-5

Stoeltzing, 2003, Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice, Int J Cancer, 104, 496, 10.1002/ijc.10958

Khalili, 2006, A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo, Mol Cancer Ther, 5, 2271, 10.1158/1535-7163.MCT-06-0100

Livant, 2000, Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma, Cancer Res, 60, 309

Läubli, 2010, Selectins promote tumor metastasis, Semin Cancer Biol, 20, 169, 10.1016/j.semcancer.2010.04.005

Borsig, 2011, Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase, Neoplasia, 13, 445, 10.1593/neo.101734

D׳Arena, 2014, Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498, Expert Opin Ther Pat, 24, 821, 10.1517/13543776.2014.915942

Negi, 2012, Role of CD44 in tumour progression and strategies for targeting, J Drug Target, 20, 561, 10.3109/1061186X.2012.702767

Leong, 2014, Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis, Cell Rep, 8, 1558, 10.1016/j.celrep.2014.07.050

Revach, 2014, The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion, Cell Adhes Migr, 8, 215, 10.4161/cam.27842

Omidi, 2014, Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines, Bioimpacts, 4, 55

Gao, 2014, Role of inflammation-associated microenvironment in tumorigenesis and metastasis, Curr Cancer Drug Targets, 14, 30, 10.2174/15680096113136660107

Chanmee, 2014, Tumor-associated macrophages as major players in the tumor microenvironment, Cancers, 6, 1670, 10.3390/cancers6031670

Landskron, 2014, Chronic inflammation and cytokines in the tumor microenvironment, J Immunol Res, 2014, 149185, 10.1155/2014/149185

Dhani, 2015, The clinical significance of hypoxia in human cancers, Semin Nucl Med, 45, 110, 10.1053/j.semnuclmed.2014.11.002

Barar, 2013, Dysregulated pH in tumor microenvironment checkmates cancer therapy, Bioimpacts, 3, 149

Hammond, 2014, The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics, Front Oncol, 4, 195, 10.3389/fonc.2014.00195